C-type natriuretic peptide (CNP) and its downstream signaling regulate myocardial remodeling, cardiac function, vascular tone, angiogenesis, and fibrosis in the cardiovascular system.
The natriuretic peptide family consists of three biologically active peptides: ANP, BNP, and CNP. CNP is more widely expressed than the other two peptides, with significant levels in the central nervous system, osteochondral system, and vascular system. The receptor that is mainly targeted by CNP is GC-B, which differs from GC-A, the receptor targeted by ANP and BNP. Consequently, the actions of CNP differ somewhat from those of ANP and BNP. CNP knockout leads to severe dwarfism, and there has been important research into the role of CNP in the osteochondral system. As a result, a CNP analog is now available for clinical use in patients with achondroplasia. In the cardiovascular system, CNP and its downstream signaling are involved in the regulatory mechanisms underlying myocardial remodeling, cardiac function, vascular tone, angiogenesis, and fibrosis, among others. This review focuses on the roles of CNP in the cardiovascular system and considers its potential for clinical application in the treatment of cardiovascular diseases.
Nakagawa et al. (Wed,) conducted a review in Cardiovascular diseases. C-type natriuretic peptide (CNP) was evaluated. C-type natriuretic peptide (CNP) and its downstream signaling regulate myocardial remodeling, cardiac function, vascular tone, angiogenesis, and fibrosis in the cardiovascular system.